

#5  
PTO/SB/

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	2
-------	---	----	---

<b>Application Number</b>	09/826716
<b>Filing Date</b>	04/05/2001
<b>First Named Inventor</b>	Karpusas, Michael
<b>Group Art Unit</b>	1754
<b>Examiner Name</b>	Not assigned
<b>Attorney Docket Number</b>	A062 US

[illegible]

RECEIVED  
FEB 25 2002  
TC 1700

[illegible]

*[Signature]*


08/03

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **2**

### Complete if Known

Application Number	09/826716
Filing Date	04/05/2001
First Named Inventor	Karpusas, Michael
Group Art Unit	1754
Examiner Name	Not assigned
Attorney Docket Number	A062 US

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
mm	BA	Baldwin, Eric et al., 1998, Chemical Abstracts XP-002132455, 6:7:923-925, "Cation binding to the integrin CD11 I domain and activation" /	
	BB	Gotwals, Philip et al., 1996, J. Clin. Invest., 97:2469-2477, "The alpha1beta1 Integrin Is Expressed during Neointima Formation in Rat Arteries and Mediates Collagen Matrix Reorganization" /	
	BC	Nolte, Matthais et al., 1999, Federation of European Biochemical Societies, 452:3:379-385, "Crystal structure of the alpha1beta1 integrin I-domain: insights into integrin I-domain function"	
	BD	Qu, Aidong et al., 1995, Proc. Natl Acad. Sci., XP-002132453, 92:10277-10281, "Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, alphaLBeta2 integrin" /	
mm	BE	Salminen T.A. et al., 1999, Chemical Abstracts XP-002132454, 131:239407, "Production, crystallization and preliminary X-rays analysis of the human integrin alpha1 I-domain" -	

RECEIVED  
FEB 25 2002  
TC 1700

Examiner  
Signature

Date  
Considered

02/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.